Table I.
Demographics of the participants of the granulosa cell metabolism studies.
| Clinical data | Control (n = 12) | PCOS (n = 8) | Metformin (n = 8) | Significance |
|---|---|---|---|---|
| Age (years) | 34.4 ± 1.4 | 31.5 ± 1.2 | 34.4 ± 1.3 | ns |
| Duration of infertility (years) | 3.2 ± 0.7 | 4.1 ± 0.8 | 3.4 ± 0.7 | ns |
| BMI (kg/m2) | 25.5 ± 1.6 | 26.0 ± 1.9 | 29.8 ± 1.5 | ns |
| Serum FSH (IU/l) | 6.8 ± 0.6 | 5.5 ± 0.5 | 5.7 ± 0.5 | ns |
| Total days of stimulation | 10.2 ± 0.2 | 12.4 ± 0.9 | 10.4 ± 0.5 | ns |
| Total dose of exogenous FSH IU | 2405 ± 264 | 2692 ± 382 | 1885 ± 303 | ns |
| Total number of follicles developed | 23.3 ± 2.0 | 31.1 ± 3.0 | 23.8 ± 4.0 | ns |
| Number of MII oocytes/patient | 16.3 ± 2.0 | 12.4 ± 2.8 | 11.1 ± 1.0 | PCOS versus Control, P = 0.046 Others – ns |
| Fertilization rate/MII oocyte | 67 ± 0.2% | 67 ± 0.2% | 60 ± 0.2% | ns |
| Positive pregnancy rate per cycle started | 50% | 75% | 63% | ns |
| Clinical pregnancy rate per cycle started | 50% | 57% | 44% | ns |
The values are mean ± SEM except for fertilization, positive pregnancy and clinical pregnancy rate. Chi2 and Kruskal–Wallis tests were used for statistical analysis.
PCOS: polycystic ovary syndrome; MII: metaphase II; Metformin: women with PCOS who had been treated with metformin.